United States Drug Patent 6,561,977: Claim Scope, Thalidomide REMS Coverage, Expiration and Patent Landscape

U.S. Patent No. 6,561,977 protected a controlled-distribution method for dispensing a drug only after a computerized risk assessment generated an approval code. The patent was assigned to Celgene Corporation and was directed principally to a risk-management and prescription-authorization system, not to thalidomide’s chemical composition, formulation, or therapeutic use.

The claims expressly cover thalidomide and teratogenic-risk controls, including pregnancy testing, contraception, informed consent, periodic monitoring, pharmacy authorization, and risk assessment involving sexual partners or recipients of bodily fluids. The patent’s expected 20-year term expired in November 2020, leaving no enforceable patent rights under this patent today. Its claims remain relevant to historical analysis of Celgene’s S.T.E.P.S. program and to the development of later risk-evaluation and mitigation strategies.

What does U.S. Patent 6,561,977 protect?

U.S. Patent 6,561,977 protects a controlled-access prescription process with five required functional elements:

The sponsor or administrator defines patient risk groups.
The system collects patient information relevant to an adverse event.
The patient is assigned to one or more risk groups.
The system determines whether the risk is acceptable.
The system generates an approval code that a pharmacy must retrieve before dispensing the drug.

Claim 1 is the core independent claim. It requires both clinical risk assessment and a pharmacy-level dispensing block. A database that merely records prescriptions would not necessarily satisfy the claim. The claimed process requires a pharmacy to fill the prescription only after retrieving an approval code from a computer-readable storage medium.

The patent is therefore a process patent covering coordinated operation among:

The patient;
The prescribing physician;
The pharmacy;
The computerized database;
The risk-assessment protocol; and
The approval-code mechanism.

The claim does not require a particular computer architecture, database vendor, communications network, or software language. Its scope is defined functionally.

What are the key limitations of claim 1?

Claim 1 contains several limitations that materially narrow its scope.

Pharmacy retrieval of an approval code

The pharmacy must retrieve an approval code before filling the prescription. A system that authorizes a prescription internally but does not require pharmacy retrieval may present a noninfringement argument.

The claim also requires that the prescription be filled only after the approval code is retrieved. A post-dispensing recordkeeping system would not satisfy the temporal requirement.

Predefined patient risk groups

The system must define multiple risk groups based on predefined risk parameters for the drug. A generic clinical review process without defined risk-group assignments may fall outside the claim.

Patient-specific information

The information collected must be probative of whether an adverse side effect is likely to occur. The claim does not require one specific data element. It can encompass pregnancy status, diagnostic results, medication use, disease status, behavioral information, or other risk factors.

Acceptability determination

The system must determine whether the risk is acceptable based on the collected information and the assigned risk group. Merely collecting information without making an acceptability determination does not meet this limitation.

Approval-code generation

The approval code is generated only after the system determines that the risk is acceptable. An unrestricted prescription number, billing code, or ordinary prior-authorization number may not satisfy the claim unless it performs the claimed approval function.

How do claims 2 through 8 expand the controlled-distribution method?

Claims 2 through 8 add administrative, counseling, and consent requirements.

Claim	Additional limitation
2	Registration of the prescribing physician
3	Registration of the pharmacy
4	Patient counseling and risk-avoidance instructions
5	Full disclosure of risks
6	Informed consent before dispensing
7	Registration of informed consent before approval-code generation
8	Transmission of risk-group assignment and consent by facsimile, with optical-character recognition

Claims 2 and 3 extend the system beyond patient authorization. The physician and pharmacy become registered participants in the distribution network.

Claims 4 through 7 create a layered informed-consent process. The prescription cannot be filled until counseling and consent have occurred, and claim 7 requires that consent be entered into the computer-readable medium before the approval code is generated.

Claim 8 is technologically specific. It covers a fax-based process in which documents are interpreted through optical-character recognition software. Because claim 8 depends on claim 7, it requires all limitations of claims 1 through 7 as well as the fax and OCR process.

What diagnostic testing is covered by claims 9 through 12?

Claims 9 through 12 cover risk assessment that uses diagnostic testing. The diagnostic information may establish:

The onset of the adverse side effect;
A disease or condition for which the drug is contraindicated; or
A genetic risk factor.

Claim 10 expressly covers genetic testing. The claims do not limit the test to a particular assay, biomarker, laboratory, or testing platform.

In the thalidomide context, pregnancy testing is a central example, although the patent’s diagnostic-testing claims are drafted more broadly. The testing could also concern concomitant medications, disease status, laboratory abnormalities, or other factors associated with adverse effects.

Does the patent cover fetal and sexual-partner risk?

Yes. Claims 14 through 16 extend the adverse-event analysis beyond the patient.

The claims cover an adverse effect likely to arise in:

A fetus carried by the patient;
A recipient of the patient’s bodily fluid; and
A sexual partner of the patient.

Claims 23 through 27 narrow this concept to teratogenic effects and expressly identify thalidomide. Claim 26 covers a fetus carried by a recipient of the patient’s bodily fluid, while claim 27 specifies that the recipient may be a sexual partner.

These provisions are significant because they address paternal exposure and potential fetal exposure through semen, not only pregnancy in the treated patient. They also show that the patent was designed around a broad reproductive-risk management framework.

What thalidomide protections are contained in claims 23 through 29?

Claims 23 through 29 create the patent’s most drug-specific coverage.

Claim	Thalidomide-related subject matter
23	Teratogenic adverse effect
24	Thalidomide
25	Fetal risk to the treated patient
26	Fetal risk to a bodily-fluid recipient
27	Sexual partner as recipient
28	Pregnancy-test results
29	Prescription duration of no more than about 28 days

Claim 24 is a dependent claim directed expressly to thalidomide. It does not claim thalidomide itself. It claims the controlled-delivery method of claim 23 when the drug is thalidomide.

Claim 29 links pregnancy testing with a dispensing period of approximately 28 days. This corresponds to a monthly authorization and monitoring cycle. The claim is narrower than claim 1 because it requires the thalidomide, teratogenic-risk, pregnancy-testing, and 28-day dispensing limitations.

What periodic monitoring requirements are covered?

Claims 17 through 21 require continuing monitoring after the initial risk determination.

The system must:

Define a second information set for each risk group;
Collect that information periodically; and
Enter the information into the computer-readable medium.

Claim 18 covers a behavioral and compliance survey. Claim 19 specifies telephonic administration through an integrated voice-response system. Claim 20 covers pregnancy-test results for a female of childbearing potential. Claim 21 identifies an interval of approximately 28 days.

These claims address longitudinal compliance, not only the initial dispensing decision. A system that performs one-time screening but does not periodically collect and store risk information would not meet claims 17 through 21.

What do claims 30 through 34 cover for drug interactions?

Claims 30 through 34 address adverse effects that arise when the drug is taken with another drug.

The system must evaluate whether:

The patient is likely to take the drug with another drug;
Diagnostic testing shows evidence of use of the other drug; or
Testing indicates onset of the adverse effect.

This category extends the patent beyond reproductive teratogenicity. It covers controlled dispensing based on interaction risk, including testing for evidence that the patient is taking a contraindicated co-medication.

The claims remain method claims. They do not claim a particular drug combination, assay, database, or clinical decision rule.

How strong is the patent estate for U.S. Patent 6,561,977?

The patent had meaningful historical scope but limited current commercial value because it expired.

Historical strengths

The patent’s strongest features were:

Functional coverage of the complete controlled-dispensing workflow;
Explicit pharmacy authorization requirements;
Risk-group assignment;
Approval-code generation;
Informed consent and counseling;
Pregnancy testing and 28-day dispensing;
Coverage of fetal and sexual-partner risk;
Coverage of diagnostic and genetic testing; and
Coverage of concomitant-drug risk.

The broadest protection was claim 1. The thalidomide claims were narrower but closely aligned with the operating requirements of a teratogenic-risk program.

Historical vulnerabilities

Potential validity and infringement issues included:

Whether the claimed computer-based process was patent-eligible under the law applicable at the time;
Whether prior art disclosed computerized prescription authorization and patient-risk registries;
Whether a particular pharmacy system actually required retrieval of the claimed approval code;
Whether a sponsor’s system performed the claimed risk acceptability determination;
Whether consent and counseling data were entered before approval-code generation; and
Whether generic dispensing systems used materially different workflows.

The patent issued in 2003, before the Supreme Court’s later decisions on abstract ideas and computer-implemented methods. A modern validity analysis would consider cases such as Alice Corp. v. CLS Bank International, although the patent’s expiration generally removes the practical need for a present-day validity challenge.

When did U.S. Patent 6,561,977 expire?

The patent’s 20-year term ran from its earliest applicable nonprovisional filing date and expired in November 2020. The patent is no longer enforceable against generic manufacturers, pharmacies, prescribers, sponsors, or software providers.

Event	Date or status
Patent	U.S. Patent No. 6,561,977
Title	Method for delivering a drug to a patient while restricting access
Assignee	Celgene Corporation
Issue date	May 13, 2003
Patent type	Method and controlled-distribution process
Expected statutory expiration	November 2020
Current enforceability	Expired

The expiration of this patent did not eliminate FDA authority to require a risk-management program. Patent rights and FDA safety controls are separate legal mechanisms.

What was the FDA and Orange Book status?

U.S. Patent 6,561,977 was not a conventional composition-of-matter patent and was not the type of patent ordinarily relied on to block an ANDA through an Orange Book listing.

The FDA-approved product associated with the claims was thalidomide, marketed by Celgene as Thalomid. FDA approved thalidomide in 1998 for erythema nodosum leprosum and later approved it in combination with dexamethasone for newly diagnosed multiple myeloma. FDA required controlled distribution because of the drug’s known teratogenicity.[1]

The S.T.E.P.S. program, later replaced by the Thalidomide REMS, required measures including:

Prescriber and pharmacy registration;
Patient enrollment;
Pregnancy testing;
Contraception requirements;
Counseling;
Informed consent; and
Limited dispensing periods.

These requirements were regulatory controls, not evidence that the patent remained enforceable. FDA’s REMS authority derives from the Federal Food, Drug, and Cosmetic Act and implementing regulations, not from patent claims.[2]

Were there Paragraph IV challenges to this patent?

A Paragraph IV certification applies to patents listed by FDA in the Orange Book for an approved drug product. Because 6,561,977 was a method-of-delivery and risk-management patent rather than a conventional drug-product patent, it was not the principal type of patent that would ordinarily generate a Paragraph IV generic challenge.

Generic thalidomide applicants could still face other listed patents, labeling requirements, REMS obligations, and regulatory questions. A Paragraph IV certification against a composition, formulation, or method-of-use patent would be distinct from any dispute over the expired 6,561,977 patent.

No current Paragraph IV exposure remains under 6,561,977 because the patent has expired.

What patent litigation and licensing issues affected thalidomide distribution?

Celgene’s commercial control of thalidomide rested on a combination of regulatory exclusivity, product patents, distribution controls, trademark and brand rights, and the S.T.E.P.S. program. The controlled-distribution patent was one component of that broader strategy.

The most commercially important barriers were:

FDA approval and labeling;
Compliance with the thalidomide REMS;
Product sourcing and manufacturing controls;
Patent protection for thalidomide uses and formulations;
Institutional procurement requirements;
Physician and pharmacy enrollment; and
Commercial supply and distribution agreements.

Public regulatory materials identify Celgene as the sponsor of Thalomid and identify the S.T.E.P.S. program as the controlled-distribution mechanism.[1] The patent record alone does not establish a separate third-party license covering the claims of 6,561,977. No license should be presumed solely from a manufacturer’s participation in the FDA-required program.

How does this patent compare with composition and formulation patents?

Patent category	Subject matter	Relevance to generic entry
Composition patent	The active pharmaceutical ingredient	Usually the strongest barrier before expiration
Formulation patent	Dosage form, excipients, release profile, or stability	Can delay or complicate substitution
Method-of-use patent	Treatment of a disease or patient population	May support an ANDA Paragraph IV dispute
Controlled-distribution patent	Authorization, monitoring, and dispensing workflow	Usually affects system operation rather than drug manufacture
Regulatory exclusivity	FDA statutory protection	Independent of patent validity
REMS requirement	Safety-control program	Can remain after patent expiration

U.S. Patent 6,561,977 is best classified as a controlled-distribution or method-of-delivery patent. It did not prevent a manufacturer from making thalidomide merely because the manufacturer used a different formulation. Its principal risk was that a competing sponsor, pharmacy network, or distributor could implement a substantially similar authorization workflow.

What generic entry risks existed for thalidomide?

After patent expiration, generic entry still required compliance with FDA requirements. The principal issues were:

Demonstrating bioequivalence;
Obtaining an approved ANDA;
Adopting required labeling;
Complying with the thalidomide REMS or successor risk-control program;
Maintaining registered prescribers and pharmacies;
Conducting pregnancy testing and counseling; and
Preventing dispensing outside authorized channels.

The expired patent removed one intellectual-property barrier but did not remove the teratogenicity-related regulatory controls. A generic manufacturer could avoid infringement risk under 6,561,977 by using a materially different workflow, but it still had to satisfy FDA safety requirements.

Did this patent create biosimilar risk?

No. Thalidomide is a small-molecule drug, not a biologic. Biosimilar approval under the Public Health Service Act does not apply.

The relevant competitive pathway was an ANDA for a generic drug, not a biosimilar application. The patent therefore had no direct biosimilar-risk profile. Its commercial relevance was tied to generic thalidomide and to other drugs using comparable restricted-access systems.

What manufacturing and geographic barriers remained after expiration?

The patent did not claim a manufacturing process, synthetic route, crystal form, polymorph, or pharmaceutical composition. It therefore did not create a direct manufacturing barrier.

Its geographic scope was limited to the United States. Foreign counterparts, if any, required separate country-by-country analysis. Expiration of the U.S. patent did not determine the status of corresponding rights in Europe, Canada, Japan, or other jurisdictions.

After expiration, the most important operational barriers were:

FDA registration and approval;
REMS compliance;
Controlled supply-chain management;
Qualified manufacturing capacity;
Pharmacovigilance;
Country-specific labeling; and
National patent and regulatory rights outside the United States.

Key Takeaways

U.S. Patent 6,561,977 covered a computerized controlled-distribution method, not thalidomide itself.
Claim 1 required risk-group assignment, patient-risk information, an acceptability determination, and pharmacy retrieval of an approval code.
Claims 23 through 29 specifically addressed thalidomide, teratogenicity, pregnancy testing, fetal exposure, sexual partners, and 28-day dispensing.
Claims 17 through 21 covered periodic monitoring, behavioral surveys, IVR calls, and pregnancy-test updates.
Claims 30 through 34 addressed adverse effects caused by drug combinations.
The patent expired in November 2020 and presents no current enforcement risk.
The patent was not the primary type of patent used for Orange Book-based generic blocking.
FDA REMS obligations continued independently of patent expiration.
Thalidomide presents generic, not biosimilar, competition.
The patent did not create a manufacturing-process or international patent barrier.

FAQs

Does U.S. Patent 6,561,977 claim thalidomide itself?

No. Claim 24 identifies thalidomide only as the drug used in the claimed teratogenic-risk delivery method. The patent does not claim thalidomide’s chemical structure.

Can a pharmacy infringe the patent by using a pregnancy-test requirement?

Not by that fact alone. Infringement would require performance of all limitations of an applicable claim, including the claimed risk assessment, computer-readable record, acceptable-risk determination, and approval-code retrieval process. The patent has also expired.

Did expiration of the patent eliminate the Thalidomide REMS?

No. Patent expiration and FDA safety requirements are separate. FDA could continue requiring controlled distribution, pregnancy testing, counseling, and enrollment after patent expiration.[1,2]

Is a 28-day dispensing limit independently protected by this patent?

No. The approximately 28-day limit appears in dependent claim 29 and requires the limitations of the claims from which it depends, including thalidomide, teratogenic risk, and pregnancy-test information.

Could the patent cover a restricted-access system for a drug other than thalidomide?

Yes. Claim 1 is not limited to thalidomide. Claims 23 through 29 narrow the invention to teratogenic risk and thalidomide, but the broader independent claim can cover controlled delivery of other drugs if every claim limitation is met.

References

U.S. Food and Drug Administration. (1998). Thalomid (thalidomide) approval and safety information. FDA.
U.S. Food and Drug Administration. (2024). Risk evaluation and mitigation strategies. FDA.
United States Patent and Trademark Office. (2003). U.S. Patent No. 6,561,977: Method for delivering a drug to a patient while restricting access. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	1437201	⤷ Start Trial
Australia	2005201675	⤷ Start Trial
Australia	780486	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,561,977

Summary for Patent: 6,561,977